Get a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORECreative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsTo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE HighlightsAll products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
The genetically modified anti-MLANA TCR-NK cell is designed to target to the specific epitope-HLA complex. The TCR-NK is expected to show antigen-specific cytotoxicity against MLANA antigen via the introduced TCR were successfully produced.
| Sub CAT. | HLA | TCR Clone | Epitope | |
| XS-0623-ZP123-SUB1 | HLA-A*02 | CB-C134 | EAAGIGILTV | |
| XS-0623-ZP123-SUB2 | HLA-A*0201 | 1D3 | EAAGIGILTV | |
| XS-0623-ZP123-SUB3 | HLA-A*0201 | 1D3HMCys | EAAGIGILTV | |
| XS-0623-ZP123-SUB4 | HLA-A*0201 | 2C2 | EAAGIGILTV | |
| XS-0623-ZP123-SUB5 | HLA-A2 | DMF4 | AAGIGILTV | |
| XS-0623-ZP123-SUB6 | HLA-A*0201 | DMF4 | ELAGIGILTV | |
| XS-0623-ZP123-SUB7 | HLA-A2 | DMF5 | AAGIGILTV | |
| XS-0623-ZP123-SUB8 | HLA-A2 | DMF5 | ELAGIGILTV | |
| XS-0623-ZP123-SUB9 | HLA-A2 | JKF6 | ALGIGILTV | |
| XS-0623-ZP123-SUB10 | HLA-A*0201 | MEL5 | AAGIGILTV | |
| XS-0623-ZP123-SUB11 | HLA-A2 | RD1-MART1 High | ELAGIGILTV | |
| XS-0623-ZP123-SUB12 | HLA-A2 | S5-4 | ELAGIGILTV | |
| XS-0623-ZP123-SUB13 | HLA-A2 | SIG35α | AAGIGILTV | |
| XS-0623-ZP123-SUB14 | HLA-A*0201 | SW-M1-29 | ELAGIGILTV | |
| XS-0623-ZP123-SUB15 | HLA-A*0201 | SW-M1-54 | ELAGIGILTV | |
| XS-0623-ZP123-SUB16 | HLA-A*0201 | SW-M1-66 | ELAGIGILTV | |
| XS-0623-ZP123-SUB17 | HLA-A*0201 | SW-M1-67 | ELAGIGILTV | |
| XS-0623-ZP123-SUB18 | HLA-A*0201 | SW-M1-9 | ELAGIGILTV | |
| XS-0623-ZP123-SUB19 | HLA-A2 | T1-S18.45 | ELAGIGILTV | |
| XS-0623-ZP123-SUB20 | HLA-A2 | α24β17 | ELAGIGILTV | |
| XS-0623-ZP123-SUB21 | HLA-A*02 | CB-C135 | EAAGIGILTV |
There are currently no customer reviews or questions for Anti-MLANA TCR-NK Cells (XS-0623-ZP123). Click the button below to contact us or submit your feedback about this product.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
